NASDAQ:TRVI
Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. reported net income of −$42.8M in fiscal 2025. Free cash flow was −$42.1M, and the diluted share count rose 32.1%.Summary generated from Trevi Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−30.2%
Debt / equityn/a
Free cash flow−$42.1M
FCF marginn/a
Share count change+32.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −32 | −30 | −34 | −52 | −49 |
| Net income | −34 | −29 | −29 | −48 | −43 |
| Free cash flow | n/a | −28 | −32 | −38 | −42 |
Recent filings
- 4Insider transaction report
Sep 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 4Insider transaction report
Jun 4, 2026 - 8-KAmendment to articles or bylaws
Jun 4, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 5, 2026 - 8-KResults of operations and financial condition
May 5, 2026 - DEF 14AProxy statement
Apr 21, 2026